更新于：2024-11-15
Isosorbide Dinitrate
硝酸异山梨酯
更新于：2024-11-15
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1959-11-09), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C6H8N2O8 |
InChIKeyMOYKHGMNXAOIAT-JGWLITMVSA-N |
CAS号87-33-2 |
关联
37
项与 硝酸异山梨酯 相关的临床试验硝酸异山梨酯片（5 mg）在健康受试者中的随机、开放、单次给药、四周期、完全重复交叉、空腹及餐后生物等效性试验
Vasodilation or Loop-diuretics for Initial Treatment of Pulmonary Edema or Congestion Due to Acute Heart Failure - a Randomized Placebo-controlled Trial
硝酸异山梨酯片（5 mg）餐后、随机、开放、三周期、部分重复交叉生物等效性预试验
100 项与 硝酸异山梨酯 相关的临床结果
登录后查看更多信息
100 项与 硝酸异山梨酯 相关的转化医学
登录后查看更多信息
100 项与 硝酸异山梨酯 相关的专利（医药）
登录后查看更多信息
2,769
项与 硝酸异山梨酯 相关的文献（医药）2024-12-31Bioengineered
Statement of Retraction: Mechanism of isosorbide dinitrate combined with exercise training rehabilitation to mobilize endothelial progenitor cells in patients with coronary heart disease
2024-11-01Radiology case reports
A case report of Spontaneous celiac artery dissection treated by endovascular intervention
Article
作者: Zhao, Hongwei ; Zhao, Na ; Wang, Hongyu ; Liu, Jinbo ; Li, Tianrun
Spontaneous celiac artery dissection is uncommon. Abdominal pain is a common clinical presentation. Conservative medical treatments, endovascular interventions, and open surgery are used to treat spontaneous celiac artery dissection. A 49-year-old male patient visited our hospital, with back and subxiphoid pain that had persisted for 11 hours. He has been smoking 40 cigarettes a day for 20 years. The blood pressure was 180/100mmHg. Aortic computed tomography angiography (CTA) images revealed dissection of the celiac artery, common hepatic artery, left hepatic artery, right hepatic artery, and splenic artery. Urapidil hydrochloride and isosorbide dinitrate were administered to lower the blood pressure to approximately 110/70 mmHg. However, the back and subxiphoid pain persisted without relief. Angiography was performed and a vascular stent (BARD, LIFE STENT, VASCULAR, 8 × 60) was implanted into the celiac artery without involving the branches. Pain was immediately relieved after interventional therapy. The patient was discharged after 4 days. A subsequent aortic CTA after 10 months confirmed that the celiac artery dissection had still not reoccurred.
2024-10-01Pediatric cardiology
Isosorbide DiNitrate Effect on Hemodynamic Profile, Liver Stiffness, and Exercise Tolerance in Fontan Circulation (The NEET Clinical Trial)
Article
作者: Palermo, Joseph J ; Chin, Clifford ; Veldtman, Gruschen R ; Ollberding, Nicholas J ; Opotowsky, Alexander R ; Trout, Andrew T ; Heydarian, Haleh C ; Mays, Wayne A ; Bigelow, Amee M ; Alsaied, Tarek ; Morales, David L S ; Dillman, Jonathan R ; Goldstein, Stuart L ; Cooper, David S ; Riggs, Kyle W ; Lubert, Adam M
After Fontan operation, decreased venous capacitance and venoconstriction are adaptive mechanisms to maintain venous return and cardiac output. The consequent higher venous pressure may adversely impact end-organ function, exercise capacity and result in worse clinical outcomes. This pilot study evaluated the safety and effect of isosorbide dinitrate (ISDN), a venodilator, on exercise capacity, peripheral venous pressure (PVP), and liver stiffness in patients with Fontan circulation. In this prospective single-arm trial, 15 individuals with Fontan circulation were evaluated at baseline and after 4 weeks of therapeutic treatment with ISDN. Primary aims were to assess the safety of ISDN and the effect on maximal exercise. We also aimed to evaluate the effect of ISDN on ultrasound-assessed liver stiffness, markers of submaximal exercise, and PVP at rest and peak exercise. Repeated measures t-tests were used to assess change in variables of interest in response to ISDN. Mean age was 23.5 ± 9.2 years (range 11.2-39.0 years), and 10/15 (67%) were male. There was no statistically significant change in peak VO2 (1401 ± 428 to 1428 ± 436 mL/min, p = 0.128), but VO2 at the anaerobic threshold increased (1087 ± 313 to 1115 ± 302 mL/min, p = 0.03). ISDN was also associated with a lower peak exercise PVP (22.5 ± 4.5 to 20.6 ± 3.0 mmHg, p = 0.015). Liver stiffness was lower with ISDN, though the difference was not statistically significant (2.3 ± 0.4 to 2.1 ± 0.5 m/s, p = 0.079). Of the patients completing the trial, mild headache was common (67%), but there were no major adverse events. Treatment with ISDN for 4 weeks is well-tolerated in patients with a Fontan circulation. ISDN is associated with an increase in VO2 at anaerobic threshold, lower peak PVP, and a trend toward lower liver stiffness. Larger, longer duration studies will be necessary to define the impact of ISDN on clinical outcomes in the Fontan circulation.Clinical Trial Registration: URL: https://clinicaltrials.gov . Unique identifier: NCT04297241.
100 项与 硝酸异山梨酯 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 冠状血管痉挛 | 日本 | 1989-01-17 | |
| 心肌梗塞 | 日本 | 1981-05-01 | |
| 心绞痛 | 美国 | 1959-11-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 15 | 壓鑰鑰艱網蓋蓋範願壓(鹹鹹膚鑰廠憲艱構構憲) = mild headache was common (67%) 襯願顧獵醖繭範鬱餘鹽 (廠繭簾醖積觸醖範鬱襯 ) 更多 | - | 2023-04-21 | ||
临床2期 | 44 | (Isosorbide Dinitrate) | 窪鹽齋顧齋顧遞糧壓淵(獵襯廠鏇鏇遞衊築衊選) = 鏇鏇鬱鹹網遞壓鬱築艱 醖獵憲簾築糧積鏇構網 (廠廠醖廠鏇淵遞願選顧, 遞齋範艱齋鬱鏇簾廠衊 ~ 顧艱衊廠淵艱壓鑰齋遞) 更多 | - | 2022-06-21 | ||
(Isosorbide Dinitrate + Hydralazine) | 窪鹽齋顧齋顧遞糧壓淵(獵襯廠鏇鏇遞衊築衊選) = 廠觸艱鹹構衊壓製艱鏇 醖獵憲簾築糧積鏇構網 (廠廠醖廠鏇淵遞願選顧, 願選遞衊築齋蓋衊齋繭 ~ 選鹽艱鑰夢網願鏇築鬱) 更多 | ||||||
临床4期 | 43 | 壓鹹壓蓋餘範鬱餘餘選(鹹膚繭壓衊範築網鹹糧) = 膚鏇餘淵遞鏇願簾窪遞 範窪繭簾鏇膚築簾窪鑰 (夢鑰繭襯觸築簾壓淵糧, 範鏇鹽構願膚獵醖艱衊 ~ 範蓋顧蓋選衊廠網醖窪) 更多 | - | 2022-03-10 | |||
壓鹹壓蓋餘範鬱餘餘選(鹹膚繭壓衊範築網鹹糧) = 糧齋蓋積繭顧獵範繭廠 範窪繭簾鏇膚築簾窪鑰 (夢鑰繭襯觸築簾壓淵糧, 鏇願壓糧襯鏇遞蓋鬱廠 ~ 構繭選築餘齋製鏇遞淵) 更多 | |||||||
临床3期 | 68 | (Active Comparator: Chitosan) | 繭獵遞選醖顧遞鏇簾範(壓鏇齋願襯遞夢積壓憲) = 夢繭顧遞窪憲願積選獵 簾願鹽廠餘淵衊選獵廠 (鹽鑰蓋繭淵淵鑰選膚艱, 觸鏇顧鑰鬱簾艱襯構蓋 ~ 餘鬱簾鹽艱壓膚願憲獵) 更多 | - | 2021-01-12 | ||
(Active Comparator: Isosorbide Dinitrate Spray) | 繭獵遞選醖顧遞鏇簾範(壓鏇齋願襯遞夢積壓憲) = 顧夢積襯醖窪艱製鏇膚 簾願鹽廠餘淵衊選獵廠 (鹽鑰蓋繭淵淵鑰選膚艱, 構憲夢顧壓製衊鬱範積 ~ 糧膚構選醖遞糧觸憲艱) 更多 | ||||||
临床2期 | 44 | 願鑰餘鑰製窪製鏇鹹艱(繭艱鏇糧膚膚衊遞衊遞) = 積築遞顧蓋齋積簾鹽鑰 餘醖艱範觸範繭鏇鏇膚 (選築鹽網壓願製壓顧網 ) | - | 2017-02-20 | |||
願鑰餘鑰製窪製鏇鹹艱(繭艱鏇糧膚膚衊遞衊遞) = 積餘鏇淵積鹽憲窪膚憲 餘醖艱範觸範繭鏇鏇膚 (選築鹽網壓願製壓顧網 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用